top of page
Publications
ASH 2021 Presentation:
Aspacytarabine (BST-236) as Monotherapy is Safe, Well-tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study
ASH 2020 Presentation:
Durable Remissions and Increased Overall Survival in AML Patients Unfit for Standard Intensive Chemotherapy Achieved with High-Dose Aspacytarabine (BST-236) Induction and Consolidation

KOLs speak of BST-236:
Aspacytarabine (BST-236) as a potential new frontline therapy option for patients with AML that are unfit for intensive chemotherapy
An AML Global Portal interview of Dr. Selina Luger during ASH 2019
bottom of page